Volume 11, Number 8—August 2005
Dispatch
Cost-Benefit of Stockpiling Drugs for Influenza Pandemic
Ran D. Balicer*†
, Michael Huerta*, Nadav Davidovitch*†, and Itamar Grotto*†
, Michael Huerta*, Nadav Davidovitch*†, and Itamar Grotto*†Table 2
Cost-benefit ratios of antiviral utilization strategies*
| Strategy | Cost-benefit ratio, relative to nonintervention |
||
|---|---|---|---|
| All costs to economy | Direct healthcare costs | ||
| NI | No intervention (base case) | Ref. | Ref. |
| 1a | Therapeutic use (all patients) | 2.44 | 0.30 |
| 1b | Therapeutic use (limited to patients at high risk) | 3.68 | 1.51 |
| 2a | Preexposure long-term prophylaxis of entire population | 0.38 | 0.04 |
| 2b | Preexposure long-term prophylaxis, limited to high-risk population | 0.37 | 0.10 |
| 3a | Postexposure short-term prophylaxis for all close contacts ("ring prophylaxis"), including treatment of index patients | 2.49 | 0.27 |
*Ref., reference value of zero divided by zero.
